---
title: "Aspire-Lakewood Holdings (ASBP) news: delisting and going concern"
url: "https://aibio.space/companies/aspire-lakewood/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ASBP delisting, going concern, Nasdaq notice and merger news: Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) seeks Nasdaq hearing on delisting."
---

ASBP Aspire-Lakewood Holdings, Inc. NASDAQ · United States

# Aspire-Lakewood Holdings (ASBP) news ASBP delisting, going concern and Nasdaq notice news

Debt Financing · 2026-08-10

## [Aspire closes $30.0 million cash acquisition and enters $22.5 million revolver](https://aibio.space/news/aspire-closes-30-0-million-cash-acquisition-enters-22-5-million/)

The senior secured revolving credit facility will help fund the cash price for Dura Driver Control Systems, along with cash on hand. The release names no lender.

## Latest Aspire-Lakewood Holdings news

1. 2025-10-17 Listings [Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) seeks Nasdaq hearing on delisting](https://aibio.space/news/aspire-biopharma-holdings-now-aspire-lakewood-holdings-seeks-nasdaq/) Nasdaq says Aspire's shares face delisting for missing the $50,000,000 market value rule and the $1.00 bid price rule. The company paid $20,000 to request a hearing, and its 2024 audit carried going-concern doubt.
2. 2025-04-18 Listings [Aspire Biopharma (now Aspire-Lakewood Holdings) gets two Nasdaq deficiency letters](https://aibio.space/news/aspire-biopharma-now-aspire-lakewood-holdings-gets-two-nasdaq/) One letter cites the $50,000,000 market value of listed securities rule, with a deadline of October 13, 2025. The other cites the $1.00 minimum bid price rule.
3. 2025-03-31 Distress [Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) files NT 10-K, delays 2024 annual report](https://aibio.space/news/aspire-biopharma-holdings-now-aspire-lakewood-holdings-files-nt-10/) Aspire Biopharma told the SEC on March 31, 2025 that it needs more time to finish its 2024 financial statements. The notice gives no reason beyond that, and its narrative refers to a 10-Q deadline that does not match the annual report it is about.
4. 2025-03-31 Distress [Aspire Biopharma (now Aspire-Lakewood Holdings) delays 2024 annual report](https://aibio.space/news/aspire-biopharma-now-aspire-lakewood-holdings-delays-2024-annual/) The company said it could not file by April 15, 2025, the original due date, because it needs more time for its financial statements.
5. 2024-12-26 Mergers [PowerUp Acquisition (now Aspire-Lakewood) gets loan of up to $500,000 before merger](https://aibio.space/news/powerup-acquisition-now-aspire-lakewood-gets-loan-up-500-000-before/) The lender is an entity controlled by Aspire Biopharma's director of investor relations. $184,543.80 had been loaned as of the filing.

## Aspire-Lakewood Holdings at a glance

- **Ticker**: ASBP

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $12.2 million

### Related companies

- [Avenir Wellness Solutions](https://aibio.space/companies/avenir-wellness-solutions/) OTC: AVRW
- [America Great Health](https://aibio.space/companies/america-great-health/) OTC: AAGH
- [Niagen Bioscience](https://aibio.space/companies/niagen-bioscience/) NASDAQ: NAGE
- [GOLDENWELL BIOTECH INC.](https://aibio.space/companies/goldenwell-biotech/) OTC: GWLL
- [ProText Mobility](https://aibio.space/companies/protext-mobility/) OTC: TXTM
- [Applied Biosciences](https://aibio.space/companies/applied-biosciences/) OTC: APPB
- [Herborium Group](https://aibio.space/companies/herborium/) OTC: HBRM
- [Nu-Med Plus](https://aibio.space/companies/nu-med-plus/) OTC: NUMD

### Also on NASDAQ

- [Tenaya Therapeutics](https://aibio.space/companies/tenaya-therapeutics/) TNYA
- [COMPASS Pathways Plc](https://aibio.space/companies/compass-pathways/) CMPS
- [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) FLNA
- [Orchestra BioMed Holdings](https://aibio.space/companies/orchestra-biomed/) OBIO
- [STAAR SURGICAL CO](https://aibio.space/companies/staar-surgical/) STAA
- [INVO Fertility](https://aibio.space/companies/invo-fertility/) IVF

## What Aspire-Lakewood Holdings does

Aspire-Lakewood Holdings, Inc., which operates as Aspire, is an early-stage biopharmaceutical company formed as a Delaware corporation in February 2025. It develops and markets sublingual delivery technology, initially for known drugs. Its lead product is a high-dose sublingual aspirin product, sometimes referred to informally as Instaprin, based on a patent-pending formulation. A clinical trial completed in July 2025 in Florida studied the pharmacokinetics of two aspirin formulations given sublingually and standard oral aspirin. The company says the results will be the backbone of a 505(b)(2) submission to the FDA planned for late 2026. The company contracts with third parties for manufacturing, including Glatt, which produced product for clinical trials, and Microsize, a contract development and manufacturing organization in Quakertown, PA, engaged in January 2026 for the next round of trials of high-dose aspirin for myocardial infarction. The company does not currently have any licensing or collaboration agreements. It is strongly considering licensing its aspirin products and expects to target the heart attack and stroke prevention market through a hospital and specialty care sales force.

| Product or program | What it is | Stage |
|---|---|---|
| High-dose sublingual aspirin (Instaprin) | Aspirin delivered sublingually for faster absorption, targeting heart attack and stroke prevention | Clinical trials completed; 505(b)(2) submission planned for late 2026 |
| Sublingual delivery technology | Patent-pending formulation for rapid sublingual absorption of drugs and nutraceuticals | Patent application filed |

Summarised from the company's [10-K/A filed Apr 8, 2026](https://www.sec.gov/Archives/edgar/data/1847345/000149315226015737/form10-ka.htm).

## Aspire-Lakewood Holdings annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$6,202](https://www.sec.gov/Archives/edgar/data/1847345/000149315226015737/) |  |
| Research and development | [$923,914](https://www.sec.gov/Archives/edgar/data/1847345/000149315226015737/) | [$144,356](https://www.sec.gov/Archives/edgar/data/1847345/000149315226015737/) |
| Net income (loss) | [-$24.5 million](https://www.sec.gov/Archives/edgar/data/1847345/000149315226015737/) | [-$1.3 million](https://www.sec.gov/Archives/edgar/data/1847345/000149315226015737/) |
| Cash from operations | [-$4.9 million](https://www.sec.gov/Archives/edgar/data/1847345/000149315226015737/) | [-$265,186](https://www.sec.gov/Archives/edgar/data/1847345/000149315226015737/) |
| Cash and equivalents | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1847345/000149315226037819/) | [$3,633](https://www.sec.gov/Archives/edgar/data/1847345/000149315226037819/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $12.2 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Aspire-Lakewood Holdings

Was Aspire-Lakewood Holdings delisted?

Our latest story on this, dated Oct 17, 2025: "Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) seeks Nasdaq hearing on delisting". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aspire-biopharma-holdings-now-aspire-lakewood-holdings-seeks-nasdaq/).

Has Aspire-Lakewood Holdings issued a going-concern warning?

Our latest story on this, dated Oct 17, 2025: "Aspire Biopharma Holdings (now Aspire-Lakewood Holdings) seeks Nasdaq hearing on delisting". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aspire-biopharma-holdings-now-aspire-lakewood-holdings-seeks-nasdaq/).

Has Aspire-Lakewood Holdings received a Nasdaq deficiency notice?

Our latest story on this, dated Apr 18, 2025: "Aspire Biopharma (now Aspire-Lakewood Holdings) gets two Nasdaq deficiency letters". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aspire-biopharma-now-aspire-lakewood-holdings-gets-two-nasdaq/).

Is Aspire-Lakewood Holdings involved in a merger or acquisition?

Our latest story on this, dated Dec 26, 2024: "PowerUp Acquisition (now Aspire-Lakewood) gets loan of up to $500,000 before merger". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/powerup-acquisition-now-aspire-lakewood-gets-loan-up-500-000-before/).

What is the ticker symbol of Aspire-Lakewood Holdings?

Aspire-Lakewood Holdings, Inc. trades under the ticker ASBP on NASDAQ.

Where is Aspire-Lakewood Holdings listed?

Aspire-Lakewood Holdings, Inc. is listed on NASDAQ.

What is the SEC CIK of Aspire-Lakewood Holdings?

The SEC Central Index Key (CIK) for Aspire-Lakewood Holdings, Inc. is 1847345. Its filings are on SEC EDGAR.

How many shares does Aspire-Lakewood Holdings have outstanding?

1,402,557 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is Aspire-Lakewood Holdings listed under?

Our directory records Aspire-Lakewood Holdings, Inc. under United States.

What does Aspire-Lakewood Holdings do?

Our directory classifies Aspire-Lakewood Holdings, Inc. as: Mixed biopharma / other operations. This is a directory classification, not a description of the pipeline.

What is the ISIN of Aspire-Lakewood Holdings?

The ISIN recorded for Aspire-Lakewood Holdings, Inc. is US7389203057.

Does aibio.space cover Aspire-Lakewood Holdings?

aibio.space lists Aspire-Lakewood Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Aspire-Lakewood Holdings incorporated?

SEC records list its state or country of incorporation as E9.

What does Aspire-Lakewood Holdings develop?

Aspire-Lakewood Holdings, Inc., which operates as Aspire, is an early-stage biopharmaceutical company formed as a Delaware corporation in February 2025. It develops and markets sublingual delivery technology, initially for known drugs.

What is High-dose sublingual aspirin (Instaprin) from Aspire-Lakewood Holdings?

High-dose sublingual aspirin (Instaprin): Aspirin delivered sublingually for faster absorption, targeting heart attack and stroke prevention Stage: Clinical trials completed; 505(b)(2) submission planned for late 2026.

## Investor discussion: Aspire-Lakewood Holdings

Members talk about Aspire-Lakewood Holdings (ASBP). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Aspire-Lakewood Holdings, newest first. Each line links the filing it comes from.

1. 2026-09-29 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226044908/form8-k.htm)
2. 2026-09-09 Financings Announced a share repurchase program. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/ex99-1.htm)
3. 2026-07-20 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226033942/form8-k.htm)
4. 2026-05-14 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226023069/form8-k.htm)
5. 2026-04-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226017054/form8-k.htm)
6. 2026-04-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/form8-k.htm)
7. 2026-03-30 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226013682/form10-k.htm)
8. 2026-02-24 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226007883/formdef14a.htm)
9. 2026-02-12 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/ex99-1.htm)
10. 2026-02-12 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226006485/formpre14a.htm)
11. 2026-01-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226004543/form8-k.htm)
12. 2026-01-06 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315226000518/form8-k.htm)
13. 2025-12-03 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315225025819/forms-1.htm)
14. 2025-11-14 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315225022580/form8-k.htm)
15. 2025-11-05 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315225020891/form8-k.htm)
16. 2025-10-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315225018512/form8-k.htm)
17. 2025-09-26 Legal Reported a change of independent auditor. SEC Form 8-K (Items 3.02,4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315225015773/form8-k.htm)
18. 2025-09-23 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315225014523/formdef14a.htm)
19. 2025-09-18 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315225014085/forms-1.htm)
20. 2025-09-08 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1847345/000164117225026871/formpre14a.htm)
21. 2025-08-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000164117225025257/form8-k.htm)
22. 2025-04-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000164117225005427/form8-k.htm)
23. 2025-04-07 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1847345/000164117225002917/form10-k.htm)
24. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1847345/000164117225001893/formnt10-k.htm)
25. 2025-02-21 Legal Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315225007898/ex99-1.htm)
26. 2024-12-26 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847345/000149315224052097/form8-k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ASBP on TradingView](https://www.tradingview.com/symbols/NASDAQ-ASBP/).

## SEC filings and registration

- **SEC name**: Aspire-Lakewood Holdings, Inc.

- **CIK**: 1847345

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: ASBP (Nasdaq), ASBPW (Nasdaq)

- **State or country of incorporation**: E9

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: 23150 FASHION DRIVE, SUITE 232, ESTERO, FL, 33928

- **Phone**: 561-704-8527

- **Shares outstanding**: 1,402,557 as of 2026-08-07 (10-Q filed 2026-08-13)

- **Former names**: Aspire Biopharma Holdings, Inc.; PowerUp Acquisition Corp.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1847345/000149315226044908/form8-k.htm) filed 2026-09-29
- [8-K](https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/form8-k.htm) filed 2026-09-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1847345/000149315226041725/form8-k.htm) filed 2026-09-08
- [8-K](https://www.sec.gov/Archives/edgar/data/1847345/000149315226039135/form8-k.htm) filed 2026-08-19
- [10-Q](https://www.sec.gov/Archives/edgar/data/1847345/000149315226037819/form10-q.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1847345/000149315226036777/form8-k.htm) filed 2026-08-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1847345/000149315226033942/form8-k.htm) filed 2026-07-20
- [8-K](https://www.sec.gov/Archives/edgar/data/1847345/000149315226029599/form8-k.htm) filed 2026-06-22

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001847345), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Aspire-Lakewood Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ASBP, recorded under United States. The directory classifies it as Mixed biopharma / other operations. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Aspire-Lakewood Holdings, Inc.

- **Ticker**: ASBP

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Mixed biopharma / other operations

- **ISIN**: US7389203057

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ASBP/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/aspire-lakewood/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aspire-Lakewood Holdings (ASBP) news: delisting and going concern", 2026-10-31, https://aibio.space/companies/aspire-lakewood/